Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: sales growth of 10.3% at CER 1and business EPS 2of €1.

The company projects mid to high single-digit sales growth in 2025 at constant exchange rates, excluding hyperinflation effects, and low double-digit business EPS growth before foreign exchange and ...

Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a large ...

We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with ...

French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it ...

I review privacy tools like hardware security keys, password managers, private messaging apps and ad-blocking software. I also report on online scams and offer advice to families and individuals ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Doesn’t matter that Regeneron is working on 40 different compounds, many of which could be blockbusters, doesn’t matter if their breakthrough drug Dupixent is indicated for seven gigantic ...

Doesn’t matter that Regeneron is working on 40 different compounds, many of which could be blockbusters, doesn’t matter if their breakthrough drug Dupixent is indicated for seven gigantic ...